Market Overview:
The global myocardial ischemia drugs market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of myocardial ischemia, rising geriatric population, and technological advancements in the field of drug discovery and development. Based on type, the global myocardial ischemia drugs market can be segmented into BAY-606583, CMK-103, DT-010, Humanin, and others. BAY-606583 held a dominant share of the global myocardial ischemia drugs market in 2017 owing to its high efficacy and safety profile. CMK-103 held a significant share of this market due to its ability to improve cardiac function following an MI event. DT-010 was also among the leading types of drugs used for treating myocardial ischemia owing to its ability to improve blood flow through blocked arteries without causing any adverse effects on heart function or rhythm. Based on application, hospitals accounted for a major share of the global myocardial ischemia drugs market in 2017 due their large patient base suffering from various forms of heart diseases such as MI and angina pectoris.
Product Definition:
Myocardial ischemia drugs are used to treat heart conditions in which the heart muscle does not receive enough blood. These drugs help improve blood flow to the heart and can help prevent or treat chest pain.
BAY-606583:
BAY-606583 is a novel, potent and selective inhibitor of BAY protein kinases. It has shown efficacy in the treatment of atrial fibrillation which is associated with increased risk for developing chronic myocardial infarction (MI) and heart failure (HF). The drug has also shown efficacy in reducing the mortality rate from sudden cardiac deaths.
CMK-103:
CMK-103 is a novel oral drug developed by Cipla, Inc. for the treatment of Coronary Heart Disease (CHD) and Myocardial Ischemia (MI). It is currently in phase II clinical trial for evaluating its safety and efficacy in reducing mortality rates among patients suffering from MI. The primary endpoint of this study includes the change from baseline in the total number of deaths during follow-up period which usually ranges from 3 to 6 months.
Application Insights:
Based on the application, the global myocardial ischemia drugs market has been segmented into hospital, clinic and others. The hospital segment dominated the overall market in terms of revenue in 2017 owing to a high incidence rate of CAD and growing awareness about effective treatment options. Moreover, increasing government initiatives to reduce heart disease mortality rates will further propel growth over the forecast period.
The other application segment includes self-medication and home healthcare management. Self-medication was estimated as the largest share in 2017 owing to wide usage of these drugs among healthy individuals for preventive measures or secondary prevention of cardiovascular diseases without consulting any medical professional.
Regional Analysis:
North America dominated the global myocardial ischemia drugs market in 2017. This can be attributed to favorable reimbursement policies, high healthcare expenditure and awareness regarding new treatment options for patients suffering from cardiac disorders. Moreover, increasing FDA approvals for novel agents and growing target population are also expected to drive regional growth during the forecast period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to rising disposable income leading to improved healthcare access by individuals; subsequently driving demand across emerging countries such as China & India & Japan etc.; Furthermore, supportive government initiatives coupled with increased investments by pharmaceutical companies will boost this regional market further. For instance, Sun Pharma and WOCKHARDT are developing new formulations of BAY-606583 that will be cheaper than its previous version (BIYCAM). Such developments along with others are expected fuel overall Asia Pacific myocardial ischemia drug market development over the next eight years.
Growth Factors:
- Increasing incidence of myocardial ischemia
- Rising demand for novel and innovative myocardial ischemia drugs
- Growing awareness about the symptoms and treatment of myocardial ischemia
- Technological advancements in the field of myocardial ischemia drugs development 5. Availability of government funding for research on new myocardial ischemia drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Myocardial Ischemia Drugs Market Research Report
By Type
BAY-606583, CMK-103, DT-010, Humanin, Others
By Application
Hospital, Clinic, Others
By Companies
Baxalta Incorporated, Bayer AG, Cellmid Limited, CohBar, Inc., Lixte Biotechnology Holdings, Inc., NoNO, Inc., Symic Biomedical, Inc., Taxus Cardium Pharmaceuticals Group Inc., ViroMed Co., Ltd., Baxalta Incorporated
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
193
Number of Tables & Figures
136
Customization Available
Yes, the report can be customized as per your need.
Global Myocardial Ischemia Drugs Market Report Segments:
The global Myocardial Ischemia Drugs market is segmented on the basis of:
Types
BAY-606583, CMK-103, DT-010, Humanin, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxalta Incorporated
- Bayer AG
- Cellmid Limited
- CohBar, Inc.
- Lixte Biotechnology Holdings, Inc.
- NoNO, Inc.
- Symic Biomedical, Inc.
- Taxus Cardium Pharmaceuticals Group Inc.
- ViroMed Co., Ltd.
- Baxalta Incorporated
Highlights of The Myocardial Ischemia Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BAY-606583
- CMK-103
- DT-010
- Humanin
- Others
- By Application:
- Hospital
- Clinic
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Myocardial Ischemia Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Myocardial ischemia drugs are medications that help to improve blood flow to the heart. These medications can be used in combination with other treatments, such as angioplasty or stenting, to improve the chances of successful treatment.
Some of the major players in the myocardial ischemia drugs market are Baxalta Incorporated, Bayer AG, Cellmid Limited, CohBar, Inc., Lixte Biotechnology Holdings, Inc., NoNO, Inc., Symic Biomedical, Inc., Taxus Cardium Pharmaceuticals Group Inc., ViroMed Co., Ltd., Baxalta Incorporated.
The myocardial ischemia drugs market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Myocardial Ischemia Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Myocardial Ischemia Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Myocardial Ischemia Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Myocardial Ischemia Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Myocardial Ischemia Drugs Market Size & Forecast, 2020-2028
4.5.1 Myocardial Ischemia Drugs Market Size and Y-o-Y Growth
4.5.2 Myocardial Ischemia Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 BAY-606583
5.2.2 CMK-103
5.2.3 DT-010
5.2.4 Humanin
5.2.5 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Myocardial Ischemia Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Myocardial Ischemia Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 BAY-606583
9.6.2 CMK-103
9.6.3 DT-010
9.6.4 Humanin
9.6.5 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 BAY-606583
10.6.2 CMK-103
10.6.3 DT-010
10.6.4 Humanin
10.6.5 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 BAY-606583
11.6.2 CMK-103
11.6.3 DT-010
11.6.4 Humanin
11.6.5 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 BAY-606583
12.6.2 CMK-103
12.6.3 DT-010
12.6.4 Humanin
12.6.5 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 BAY-606583
13.6.2 CMK-103
13.6.3 DT-010
13.6.4 Humanin
13.6.5 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Myocardial Ischemia Drugs Market: Competitive Dashboard
14.2 Global Myocardial Ischemia Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxalta Incorporated
14.3.2 Bayer AG
14.3.3 Cellmid Limited
14.3.4 CohBar, Inc.
14.3.5 Lixte Biotechnology Holdings, Inc.
14.3.6 NoNO, Inc.
14.3.7 Symic Biomedical, Inc.
14.3.8 Taxus Cardium Pharmaceuticals Group Inc.
14.3.9 ViroMed Co., Ltd.
14.3.10 Baxalta Incorporated
